CellSeed Inc. (JP:7776)
:7776
Want to see JP:7776 full AI Analyst Report?
7776 Stock Chart & Stats
¥259.00
-¥7.00(-1.73%)
At close: 4:00 PM EST
¥259.00
-¥7.00(-1.73%)
Day’s Range― - ―
52-Week Range¥231.00 - ¥668.00
Previous CloseN/A
Volume900.50K
Average Volume (3M)621.90K
Market Cap
¥11.70B
Enterprise Value¥7.80B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.28
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.31
Shares Outstanding38,873,920
10 Day Avg. Volume981,780
30 Day Avg. Volume621,903
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Cell‑sheet TechnologyCellSeed's focus on cell sheet engineering positions it in a narrow, specialized segment of regenerative medicine with high technical barriers and specialized manufacturing know‑how. That niche expertise supports durable differentiation, long development cycles, and potential long‑term partnerships with hospitals and developers.
Healthy Gross MarginsConsistently high gross margins indicate solid underlying unit economics for CellSeed's product and service offerings. If revenue scales, these margins provide structural capacity to fund R&D and commercialization, improving operating leverage over the medium term despite current fixed costs.
Conservative Financial LeverageLow debt levels give the company financial flexibility to pursue development milestones and manage clinical timelines without heavy near‑term interest burdens. Conservative leverage reduces insolvency risk and preserves optionality for equity or partnership financing when needed.
Bears Say
Sharp Revenue DeteriorationA more than 50% revenue drop undermines scalability and indicates either lost contracts, delayed product rollouts, or demand issues. Such structural revenue weakness strains the ability to cover fixed costs, slows pathway to breakeven, and raises the probability of further funding needs over months.
Persistent Operating Cash BurnSustained negative operating and free cash flows show the business is not self‑funding and must rely on external financing. Persistent cash burn increases dilution risk, limits strategic optionality, and can hamper timely investment in clinical development and commercialization over the medium term.
Very Large Operating Losses And Equity ErosionExtremely wide losses and a material drop in equity signal structural unprofitability and capital erosion. This weakens returns, raises concerns about future fundraising capacity and dilution, and can impair confidence from partners and investors over a multi‑month horizon.
CellSeed Inc. News
7776 FAQ
What was CellSeed Inc.’s price range in the past 12 months?
CellSeed Inc. lowest stock price was ¥231.00 and its highest was ¥668.00 in the past 12 months.
What is CellSeed Inc.’s market cap?
CellSeed Inc.’s market cap is ¥11.70B.
When is CellSeed Inc.’s upcoming earnings report date?
CellSeed Inc.’s upcoming earnings report date is May 13, 2026 which is in 23 days.
How were CellSeed Inc.’s earnings last quarter?
CellSeed Inc. released its earnings results on Feb 13, 2026. The company reported -¥7.31 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.31.
Is CellSeed Inc. overvalued?
According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued.
Does CellSeed Inc. pay dividends?
CellSeed Inc. does not currently pay dividends.
What is CellSeed Inc.’s EPS estimate?
CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSeed Inc. have?
CellSeed Inc. has 38,873,920 shares outstanding.
What happened to CellSeed Inc.’s price movement after its last earnings report?
CellSeed Inc. reported an EPS of -¥7.31 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.305%.
Which hedge fund is a major shareholder of CellSeed Inc.?
Currently, no hedge funds are holding shares in JP:7776
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSeed Inc.
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―